The use of SABR is well established in many cancers, however, its application within kidney cancer is relatively new. This is largely due to the historical notion that renal cell carcinoma (RCC) is highly radioresistant.

Anal cancer rates are increasing, and there is a need to improve coordination across the spectrum of anal cancer care, from diagnosis, treatment, recovery and survivorship. Failure to understand the roles of all the multidisciplinary aspects of care leads to suboptimal patient care.  

SBRT for oligometastatic disease of mixed histologies has been shown to improve progression-free and even overall survival. A large cooperative group study recently demonstrated that there was no overall survival advantage seen when constrained to breast cancer alone.

When implementing newer technologies practices often rely on vendor training, an evaluation of published literature, and collaboration with others experienced in the technology. Incident learning has a critical role in radiation therapy and may be most important in new and emerging technologies.